NMDA antagonists for refractory seizures

Neurocritical Care

Volumn 20, Issue 3, 2014, Pages 502-513

  Zeiler, F A ^a,b   Teitelbaum, J ^b   Gillman, L M ^a   West, M ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Ketamine; NMDA antagonists; Refractory status; Status epilepticus

Indexed keywords

ANESTHETIC AGENT; ANTICONVULSIVE AGENT; KETAMINE; LIVER ENZYME; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; AMINO ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ABNORMAL LABORATORY RESULT; CONTINUOUS INFUSION; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; ELECTROENCEPHALOGRAM; EPILEPTIC STATE; EVIDENCE BASED MEDICINE; HEART ARRHYTHMIA; HUMAN; HYPERSALIVATION; INTRACTABLE EPILEPSY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; STATUS EPILEPTICUS;

DRUG RESISTANCE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; RECEPTORS, N-METHYL-D-ASPARTATE; STATUS EPILEPTICUS;

EID: 84902364799     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-013-9939-6     Document Type: Review

References (45)

1. Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3-23.
2. Claassan J, Silbergleit R, Weingart SD, Smith WD. Emergency neurological life support. Neurocrit Care. 2012;17(Suppl. 1):S73-8.
3. Hunter G, Young B. Status epilepticus: a review, with emphasis on refractory cases. Can J Neurol Sci. 2012;39(2):157-69.
4. Trinka E, Hofler J, Zerbs A. Causes of status epilepticus. Epilepsia. 2012;53(Suppl. 4):127-38.
5. A receptor signaling that underlie benzodiazepine-resistant seizures. Epilepsia. 2012;53(Suppl. 9):79-88.
6. Feng HJ,Mathews GC, Kao C, Macdonald RL. Alterations of GABA A-receptor function and allosteric modulation during development of status epilepticus. J Neurophysiol. 2008;99(3):1285-93. (Pubitemid 351413710)
7. Loscher W. Mechanisms of drug resistance in status epilepticus. Epilepsia. 2007;48(Suppl. 8):74-7. (Pubitemid 350045533)
8. Loscher W, Potscha H. Drug resistance in brain disease and the role of drug efflux transporters. Nat Rev Neurosci. 2005;6(8):591-602. (Pubitemid 41059334)
9. Rizzi M, Caccia S, Guiso G, Richichi C, Gorter JA, Aronica E, et al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci. 2002; 22(14):5833-9.
10. Fujikawa DG. Prolonged seizure and cellular injury: understanding the connection. Epilepsy Behav. 2005;7(Suppl. 3):S3-11.
11. Singh D, Kelly K, Rana S, Valeriano J. Use of ketamine in treating refractory status epilepticus. Epilepsia. 2009;50(Suppl. 11):63.
12. Svoronos A, Kilbride RD, Mendoza L, Szaflarski JP, Carpenter A, Claassan J, et al. Non-traditional therapies for prolonged refractory status epilepticus: a multicenter review. Epilepsia. 2011;12(Suppl. 1):3.211.
13. Rosati A, L'Erario M, Ilvento L, Pisano T, Mirable L, Guerrini R. An ongoing open-lable uncontrolled study of the efficacy and safety of ketamine in children with refractory status epilepticus. Epilepsia. 2013;54(Suppl. 3):17.
14. Bleck TP, Quigg MS, Nathan BR, Smith TL, Kapur J. Electroencephalographic effects of ketamine treatment for refractory status epilepticus. Epilepsia. 2002;43(Suppl. 7):282.
15. Gaspard N, Foreman B, Judd LM, Brenton JN, Nathan BR, McCoy BM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter review. Epilepsia. 2013;54(8):1498-503.
16. Hsieh CY, Sung PS, Tsai JJ, Hwang CW. Terminating prolonged refractory status epilepticus using ketamine. Clin Neuropharmacol. 2010;33(3):165-7.
17. Kofke WA, Bloom MJ, Van Cott A, Brenner RP. Electrographic tachyphylaxis to etomidate and ketamine used for refractory status epilepticus controlled with isoflurane. J Neurosurg Anesthesiol. 1997;9(3):269-72. (Pubitemid 27473100)
18. Kramer AH. Early ketamine to treat refractory status epilepticus. Neurocrit Care. 2012;16:299-305.
19. Kramer U, Shorer Z, Ben-Zeev B, Lerman-Sagie T, Goldberg-Stern H, Lahat E. Severe refractory status epilepticus owing to presumed encephalitis. J Child Neurol. 2005;20:184-7. (Pubitemid 40561762)
20. Mewasingh LD, Sekhara T, Aeby A, Christiaens FJC, Dan B. Oral ketamine in paediatric non-convulsive status epilepticus. Seizure. 2003;12(7):483-9. (Pubitemid 37168637)
21. Rosati A, Erario LM, Ilvento L, Checci C, Pisano T, Mirable L. Efficacy and safety of ketamine in refractory status epilepticus in children. Neurology. 2012;79(24):2355-8.
22. Gosselin-Lefebvre S, Rabinstein A, Rossetti A, Savard M. Ketamine usefulness in refractory status epilepticus: a retrospective multicenter study. Can J Neurol Sci. 2013;40(3 (Suppl. 1)):S31.
23. Al-Otaibi AD, McCoy B, Cortez M, Hutchison JS, Hahn CS. The use of ketamine in refractory status epilepticus. Can J Neurol Sci. 2010;37(3 (Suppl. 1)):S69.
24. Andrade C, Franca S, Sampaio M, Ribeiro A, Oliveira JM, Ribeiro JAM, et al. Successful use of ketamine in pediatric super-refractory status epilepticus-case report. Epilepsia. 2012;53(Suppl. 5):98.
25. Kravljanac R, Nikolic LJ, Djuric M, Jovic N, Jankovic B. Treatment of status epilepsticus in children: 15-year single center experience. Acta Pediatrica. 2010;99(Suppl. 462):107.
26. Pruss H, Holtkamp M. Ketamine successfully terminate refractory status epilepticus. Epilepsy Res. 2008;82(2-3):219-22.
27. Walker MC, Howard RS, Smith SJ, Miller DH, Shorvon SD, Hirsch SD. Diagnosis and treatment of status epilepticus on a neurological intensive care unit. QJM. 1996;89(12):913-20. (Pubitemid 27016321)
28. Robakis TK, Hirsch LJ. Literature review, case report, and expert discussion on prolonged refractory status epilepticus. Neurocrit Care. 2006;4(1):35-46. (Pubitemid 43269460)
29. Sheth RD, Gidal BE. Refractory status epilepticus: response to ketamine. Neurology. 1998;51(6):1765-6. (Pubitemid 28565277)
30. Synowiec AS, Singh DS, Yenugadhati V, Valereriano JP, Schramke CJ, Kelly KM. Ketamine use in the treatment of refractory status epilepticus. Epilepsy Res. 2013;105(1-2):183-8.
31. Ubogu EE, Sagar SM, Lerner AJ, Maddux BN, Suarez JI, Werz MA. Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. Epilepsy Behav. 2003;4(1):70-5. (Pubitemid 36546455)
32. Yeh PS, Shen HN, Chen TY. Oral ketamine controlled refractory status epilepticus in an elderly patient. Seizure. 2011;20(9):723-6.
33. Zeiler FA, Kaufmann AM, Gillman LM, West M, Silvaggio J. Ketamine for medically refractory status epilepticus after elective aneurysm clipping. Neurocrit Care. 2013;19(1):119-24.
34. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions Version 5.1.0. http://www.handbook.cochrane.org. Accessed 25 Oct 2013.
35. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement. Ann Intern Med. 2009;151(4):264-9.
36. Phillips B, Ball C, Sackett D, Straus S, Haynes B, Dawes M. Oxford Centre for evidence-based medicine levels of evidence. Version 2009. http://www.cebm.net/?o=1025. Accessed Oct 2013.
37. Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-6. (Pubitemid 351632017)
38. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ, et al. Rating quality of evidence and strength of recommendations: what is "quality of evidence" and why is it important to clinicians? BMJ. 2008;336(7651):995-8. (Pubitemid 351656090)
39. Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336(7653):1106-10. (Pubitemid 351731739)
40. Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M, Liberati A, et al. Rating quality of evidence and strength of recommendations: Incorporating considerations of resources use into grading recommendations. BMJ. 2008;336(7654):1170-3. (Pubitemid 351809277)
41. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Rating quality of evidence and strength of recommendations: going from evidence to recommendations. BMJ. 2008;336(7652):1049-51.
42. Jaeschke R, Guyatt GH, Dellinger P, Schünemann H, Levy MM, Kunz R, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ. 2008;337:a744.
43. Claassan J, Hirsch LJ, Emerson RG, Bates J, Thompson TB, Mayer SA. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology. 2001;57(6):1036-42. (Pubitemid 32880200)
44. Mayer SA, Claassen J, Lokin J, Mendelson F, Dennis LJ, Fitzsimmons BF. Refractorystatus epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol. 2002;59(2):205-10. (Pubitemid 34240935)
45. Shorvon S, Ferlisi M. The outcome of therapies in refractory and super-refractory status convulsive epilepticus and recommendations for therapy. Brain. 2012;135(Pt 8):2314-28.